Pharmacological treatment of generalized anxiety disorder

Current Topics in Behavioral Neurosciences

Volumn 2, Issue , 2010, Pages 453-467

  Baldwin, David S ^a,b   Ajel, Khalil I ^c   Garner, Matthew ^d  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

^c Hampshire Partnership Trust   (United Kingdom)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

GAD; Pregabalin; SNRI; SSRI; Treatment

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; DULOXETINE; ESCITALOPRAM; LORAZEPAM; PAROXETINE; PLACEBO; PREGABALIN; QUETIAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE; ADRENERGIC RECEPTOR AFFECTING AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT;

AGE DISTRIBUTION; ARTICLE; CLINICAL FEATURE; COMORBIDITY; DEPRESSION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DROWSINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DSM-IV; EVIDENCE BASED MEDICINE; GENERALIZED ANXIETY DISORDER; HUMAN; ICD-10; LONG TERM CARE; NAUSEA; NERVOUSNESS; NONHUMAN; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ANXIETY DISORDER; DRUG TOLERANCE; RECURRENT DISEASE; REVIEW; TIME; TREATMENT OUTCOME;

ADRENERGIC UPTAKE INHIBITORS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; DRUG TOLERANCE; HUMANS; RECURRENCE; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952269149     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/7854_2009_2     Document Type: Article

References (93)

1. Allgulander C (2008) Presented at 21st ECNP Congress, 31st August 2008, Barcelona, Spain
2. Allgulander C, Hackett D, Salinas E (2001) Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 179:15-22
3. Allgulander C, Dahl AA, Austin C et al (2004) Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 161: 1642-1649
4. Allgulander C, Florea I, Huusom AK (2006) Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 9:495-505
5. Angst J, Gamma A, Baldwin DS et al (2009) The generalized anxiety spectrum: prevalence, onset, course and outcome. Eur Arch Psychiatry Clin Neurosci 259: 37-45
6. Baldwin DS (2004) Sexual dysfunction associated with antidepressant drugs. Exp Opin Drug Safety 3:457-470
7. Baldwin DS, Ajel K (2007) The role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatric Dis Treat 3:185-191
8. Baldwin DS, Polkinghorn C (2005) Evidence-based pharmacotherapy of generalized anxiety disorder. Int J Neuropsychopharmacol 8:293-302
9. Baldwin DS, Anderson IM, Nutt DJ et al (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British association for Psychopharmacology. J Psychopharmacol 19:567-596
10. Baldwin DS, Huusom AKT, Maehlum E (2006a) Escitalopram and paroxetine in the treatment of generalised anxiety disorder. Randomised, double-blind, placebo-controlled study. Br J Psychiatry 189:264-272
11. Baldwin DS, Bridgman K, Buis C (2006b) Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. J Psychopharmacol 20:91-96
12. Baldwin DS, Reines EH, Guiton C et al (2007a) Escitalopram therapy for major depression and anxiety disorders. Ann Pharmacother 41:1583-1592
13. Baldwin DS, Montgomery SA, Nil R et al (2007b) Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 10:73-84
14. Baldwin DS, Stein DJ, Dolberg O et al (2009) How long should an initial treatment period be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum Psychopharmacol 24:269-275
15. Baldwin DS, Moreno R, Briley M (2008) Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. Hum Psychopharmacol 23:527-532
16. Ballenger JC (1999) Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry 60(suppl 22):29-34
17. Bandelow B, Baldwin DS, Dolberg OT et al (2006) What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry 67:1428-1434
18. Bandelow B, Bobes J, Ahokas A, et al (2007a) Results from a phase III study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder. Int J Psychiatry Clin Pract 11:314-315 (abstract)
19. Bandelow B, Seidler-Brandler U, Becker A et al (2007b) Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatr 8:175-187
20. Bech P (2007) Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiatry 40:163-168
21. Beekman AT, Bremmer MA, Deeg DJ et al (1998) Anxiety disorders in later life: a report from the longitudinal Aging Study Amsterdam. Int J Geriatr Psychiatry 13:717-726
22. Brawman-Mintzer O, Knapp RG, Nietert PJ (2005) Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 66:1321-1325
23. Brawman-Mintzer O, Knapp RG, RynnMet al (2006) Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 67:874-881
24. Bruce SE, Yonkers KA, Otto MW et al (2005) Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry 162:1179-1187
25. Canadian Psychiatric Association (2006) Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatr 51:9S-91S
26. Carney CE, Segal ZV, Edinger JD et al (2007) A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. J Clin Psychiatr 68:254-260
27. Cervena K, Matousek M, Prasko J et al (2005) Sleep disturbances in patients treated for panic disorder. Sleep Med 6:149-153
28. Chessick CA, Allen MH, Thase M et al (2006) Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev 3:CD006115
29. Davidson JR, DuPont RL, Hedges D et al (1999) Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 60:528-535
30. Davidson JR, Bose A, Korotzer A et al (2004) Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 19:234-240
31. Davidson JRT, Wittchen H.-U, Llorca P-M et al (2008) Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 18:673-681
32. Downing RW, Rickels K (1985) Early treatment response in anxious outpatients treated with diazepam. Acta Psychiatr Scand 72:522-528
33. Feltner D, Crockatt JG, Dubovsky SJ et al (2003) A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 23:240-249
34. Feltner D, Wittchen HU, Kavoussi R et al (2008) Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 23:18-28
35. Ferguson JM (2001) SSRI antidepressant medications: adverse effects and tolerability. Prim Care J Clin Psychiatry 3:22-27
36. Food and Drug Administration [FDA] (2006) New controversial clinical trial design gives better long-term data. FDA Week
37. Geddes JR, Carney SM, Davies C et al (2003) Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361:653-661
38. Gelenberg AJ, Lydiard RB, Rudolph RL et al (2000) Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA, 283: 3082-3088
39. Goodman WK, Bose A, Wang Q (2005) Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord 87:161-167
40. Gould RA, Otto MW, Pollack MH et al (1997) Cognitive behavioural and pharmacological treatment of generalised anxiety disorder: a preliminary meta-analysis. Behav Ther 28:285-305
41. Guy W (1976) The clinical global impression severity and impression scales. In: ECDEU Assessment Manual for Psychopathology. Rockville, MD. US Dept Health, Education and Welfare, 218-222
42. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50-55
43. Hartford J, Kornstein S, LiebowitzMet al (2007) Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 22:167-174
44. Hidalgo RB, Tupler LA, Davidson JRT (2007) An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol 21:864-872
45. Judd LL, Kessler RC, Paulus MP et al (1998) Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Survey (NCS). Acta Psychiatr Scand 98(Suppl 393):6-11
46. Kasper S, Herman B, Nivoli G et al (2009). Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol 2009. E-pub ahead of print. DOI: 10.1097/YIC.0b013e32831d7980
47. Katzman MA, Vermani M, Jacobs L et al (2008) Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J Anxiety Disord [Epub ahead of print]
48. Kessler RC, DuPont RL, Berglund (1999) Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 156:1915-1923
49. Kinrys G, Vasconcelos e Sa D, Nery F (2007) Adjunctive zonisamide for treatment refractory anxiety. Int J Clin Pract 61:1050-1053
50. Laakmann G, Schüle C, Lorkowski G et al (1998) Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacol 136:357-366
51. Lenox-Smith AJ, Reynolds A (2003) A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. Br J Gen Pract 53:772-777
52. Martin JLR, Sainz-Pardo M, Furukawa TA et al (2007) Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psychopharmacol 21:774-782
53. Mendels J, Krajewski TF, Huffer V et al (1986) Effective short-term treatment of generalized anxiety disorder with trifluoperazine. J Clin Psychiatry 47:170-174
54. Meredith C, Cutler A, Neijber A, She F, Eriksson H (2008) Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the treatment of GAD. Eur Neuropsychopharmacol 18(suppl 4):S499-S450
55. Miceli JJ, Ramey TS, Weaver JJ et al (2009) Adjunctive pregabalin treatment after partial response in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. Presented at the 162nd Annual Meeting of the American Psychiatric Association; May 16-21, 2009; San Francisco, CA
56. Mitte K, Noack P, Steil R, Hautzinger M (2005) A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J Clin Psychopharmacol 25:141-150
57. Montgomery SA, Sheehan DV, Meoni P et al (2002) Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. J Psychiatr Res 36:209-217
58. Montgomery SA, Tobias K, Zornberg GL et al (2006) Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 67:771-782
59. Montgomery S, Chatamra K, Pauer L et al (2008) Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry 193:389-394
60. Nutt DJ (2005) Overview of diagnosis and drug treatment of anxiety disorders. CNS Spectrums 10:49-56
61. Olatunji BO, Feldman G, Smits JAJ et al (2008) Examination of the decline in symptoms of anxiety and depression in generalized anxiety disorder: impact of anxiety sensitivity on response to pharmacotherapy. Depress Anx 25:167-171
62. Pande AC, Crockatt MA, Janney C et al (2000) Pregabalin treatment of GAD. Presented at: American Psychiatric Association 153rd Annual Meeting. May 13-18; Chicago, IL (Abstract NR244). Available at: http://www.psych.org/edu/other_res/lib_archives/archives/meetings/ 2000nra.pdf Accessed February 15, 2006
63. Pande AC, Crockatt JG, Feltner DE et al (2003) Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 160:533-540
64. Perugi G, Frare F, Toni C et al (2002) Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid depression or dysthymia: effectiveness, tolerability and predictors of response. Neuropsychobiol 46:145-149
65. Pohl RB, Feltner DE, Fieve RR et al (2005) Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 25:151-158
66. Pollack MH, Zaninelli R, Goddard A et al (2001) Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 62:350-357
67. Pollack MH, Meoni P, Otto MW et al (2003) Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short-and long-term studies. J Clin Psychopharmacol 23:250-259
68. Pollack MH, Simon NM, Zalta AK et al (2006) Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry 59:211-215
69. Pollack MH, Kornstein SG, Spann ME, et al (2008) Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. J Psychiatr Res [Epub ahead of print]
70. Rickels K, Schweizer E, Csanalosi I et al (1988) Long-term treatment of anxiety and risk of withdrawal: prospective study of clorazepate and buspirone. Arch Gen Psychiatr 45:444-450
71. Rickels K, Pollack MH, Sheehan DV et al (2000) Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 157:968-974
72. Rickels K, Zaninelli R, McCafferty J et al (2003) Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 160:749-756
73. Rickels K, Pollack MH, Feltner DE et al (2005) Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 62:1022-1030
74. Rickels K, Rynn M, Iyengar M et al (2006) Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. J Clin Psychiatry 67:41-47
75. Rodriguez BF, Weisberg RB, Pagano ME et al (2006) Characteristics and predictors of full and partial recovery from generalized anxiety disorder in primary care patients. J Nerv Ment Dis 194:91-97
76. Rynn MA, Siqueland L, Rickels K (2001) Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry158:2008-2014
77. Rynn M, Khalid-Khan S, Garcia-Espana F (2006) Early response and 8-week treatment outcome in GAD. Depress Anx 23:461-465
78. Rynn MA, Riddle MA, Yeung PP et al (2007) Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebocontrolled trials. Am J Psychiatry 164:290-300
79. Rynn M, Russell J, Erickson J et al (2008) Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 25:182-189
80. Simon NM, Zalta AK, Worthington JJ 3rd et al (2006) Preliminary support for gender differences in response to fluoxetine for generalized anxiety disorder. Depress Anx 23:373-376
81. Simon NM, Connor KM, LeBeau RT et al (2008) Quetiapine augmentation of paroxetine CR for the treatment of generalized anxiety disorder: preliminary findings. Psychopharmacol (Berl) 197:675-681
82. Stein DJ, Andersen HF, Goodman WK (2005) Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Ann Clin Psychiatry 17:71-75
83. Stein DJ, Baldwin DS, Dolberg OT et al (2006) Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry 67:1741-1746
84. Stein DJ, Ahokas A, de Bodinat C (2008b) Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 28:561-566
85. Stein DJ, Baldwin DS, Baldinetti F, Baldinetti F, Mandel F (2008a) Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur Neuropsychopharmacol 18:422-430
86. Stocchi F, Nordera G, Jokinen RH et al (2003) Efficacy and tolerability of paroxetine for the longterm treatment of generalized anxiety disorder. J Clin Psychiatry 64:250-258
87. Tyrer P, Baldwin DS (2006) Generalised anxiety disorder. Lancet 368:2156-2166
88. Tyrer P, Owen R, Dawling S (1983) Gradual withdrawal of diazepam after long-term therapy. Lancet 321:1402-1406
89. Tyrer P, Seivewright H, Johnson T (2004) The Nottingham Study of Neurotic Disorder: predictors of 12 year outcome of dysthymic, panic and generalised anxiety disorder. Psychol Med 34:385-394
90. Weiller E, Bisserbe JC, Maier W et al (1998) Prevalence and recognition of anxiety syndromes in five European primary care settings. A report from the WHO Study on Psychological Problems in General Health Care. Br J Psychiatr 173(suppl 34):18-23
91. Wittchen H.-U, Jacobi F (2005) Size and burden of mental disorders in Europe: a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 15:357-376
92. Wittchen H.-U, Carter RM, Pfisster H, Montgomery SA et al (2000) Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol 15:319-328
93. Wittchen H.-U, Kessler RC, Beesdo K et al (2002) Generalized anxiety disorder and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 63(suppl 8):24-34